Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics

PR Newswire June 18, 2013

Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18

Business Wire June 17, 2013

Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin's Lymphoma

Business Wire June 17, 2013

The Straight Truth, Investing in FITB, HTZ, BRCM and GILD

Marketwired June 13, 2013

Profitable Trading Secrets Revealed in SFD, GILD, CMCSA and ARR

Marketwired June 11, 2013

Gilead Sciences to Present at the Goldman Sachs 34th Annual Healthcare Conference on Tuesday, June 11

Business Wire June 10, 2013

Key to Success, How to Profit: GILD and ITUB

Marketwired June 10, 2013

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C

Business Wire June 7, 2013

Companies Taking Strategic Initiatives in Delivering Innovative Solutions to Boost Sales and Meet Customer Demands - Research Report on ResMed, Quest Diagnostics, Mettler-Toledo, Gilead, and TearLab

PR Newswire June 7, 2013

Special Situation Coming Soon, a Look Inside GILD, HL and AA

Marketwired June 7, 2013

The Real Story Behind KNDI, NWSA, GILD and CRM

Marketwired June 6, 2013

Before the Crowd, How We Found GILD, GLW, SPLS and TSM

Marketwired June 5, 2013

Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy Prospects - Research Report on Gilead, Biogen Idec, GlaxoSmithKline, Viropharma, and Celsion

PR Newswire May 31, 2013

Pre-Market Analysis on GILD, NPSP, HALO, SNTS, and ITMN

Accesswire May 30, 2013

Gilead Sciences to Present at the Deutsche Bank 38th Annual Health Care Conference on Wednesday, May 29

Business Wire May 28, 2013

European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection

Business Wire May 28, 2013

Perfect Trade Setups, How to Play GILD, CPST, BMC and INFN

Marketwired May 25, 2013

Don't Miss Gains in KO, EQR, GILD and CMCSA

Marketwired May 24, 2013

Free Research Reports on GILD, MRK, ONCY and PFE Issued by the Bedford Report

Marketwired May 23, 2013

The Reason It Trades, What's Moving ELN, DELL, GILD and KEY

Marketwired May 23, 2013